Sandoz Group AG

Informe acción SWX:SDZ

Capitalización de mercado: CHF 27.9b

Sandoz Group Crecimiento futuro

Future controles de criterios 3/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Sandoz Group de 17% y 5.2% por año respectivamente. Se prevé que el BPA crezca en un 17.1% al año. Se espera que la rentabilidad financiera sea de 17.8% en 3 años.

Información clave

17.0%

Tasa de crecimiento de los beneficios

17.09%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals10.3%
Tasa de crecimiento de los ingresos5.2%
Rentabilidad financiera futura17.82%
Cobertura de analistas

Good

Última actualización08 May 2026

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Actualización de narrativa • May 01

SDZ: Mixed Rating Shifts And Biosimilar Deals Will Shape Future P/E

The updated analyst price target for Sandoz Group has been revised by approximately CHF 1 higher, reflecting modestly adjusted assumptions around fair value, revenue growth, profit margins and future P/E as analysts balance recent target changes and rating shifts across major banks. Analyst Commentary Recent Street research around Sandoz Group shows a mix of optimism on the company’s long term potential and caution on how current pricing and expectations line up with execution risks.
Actualización de narrativa • Apr 16

SDZ: Elevated Expectations Will Test Execution On Biosimilar Expansion Plans

Analysts have raised the Sandoz Group price target by roughly CHF 2 per share, reflecting a higher assumed fair value. This is supported by a series of recent CHF 3 to CHF 9 target increases from major banks and generally constructive views, despite some rating downgrades.
Actualización de narrativa • Apr 01

SDZ: Future P/E Repricing And Biosimilar Expansion May Drive Re Rating

Analysts have lifted the price target for Sandoz Group from CHF 60.37 to CHF 81.99, citing recent initiations, upgrades and target increases that highlight a higher assumed future P/E multiple and slightly improved profit margin expectations, despite more measured revenue growth assumptions. Analyst Commentary Recent Street research on Sandoz Group presents a mixed picture, but there is a clear strand of optimism around execution, earnings quality and the scope for the shares to support higher valuation multiples.
Actualización de narrativa • Mar 18

SDZ: Mixed Rating Shifts And Biosimilar Expansion Will Shape Future P/E

Analysts have lifted the Fair Value estimate for Sandoz Group from CHF 62.57 to CHF 65.45. This reflects a series of higher Street price targets around CHF 62 to CHF 75 and updated assumptions for modestly higher revenue growth, a slightly lower profit margin profile, and a higher future P/E multiple.
Actualización de narrativa • Mar 04

SDZ: Mixed Rating Shifts And Biosimilar Pipeline Progress Will Shape Future P/E

Analysts have lifted their fair value estimate for Sandoz to about CHF 63, reflecting updated assumptions for slightly lower revenue growth, a higher profit margin and a modestly lower future P/E, along with recent mixed rating changes and higher price targets in the CHF 70 to CHF 75 range. Analyst Commentary Recent Street research on Sandoz shows a mix of optimism and caution, with price targets now clustering in the CHF 70 to CHF 75 range and ratings shifting closer to neutral.
Actualización de narrativa • Feb 18

SDZ: Richer Future P/E Assumptions Will Test Biosimilar Execution Confidence

Our latest narrative update on Sandoz Group reflects a higher implied fair value of CHF 58.42, up from CHF 52.75, supported by recent analyst price target increases and a willingness to assign a richer future P/E multiple. Analyst Commentary Recent Street research around Sandoz Group has centered on a series of price target revisions and at least one rating upgrade, which together frame how the analyst community is thinking about valuation, execution risk, and growth potential.
Actualización de narrativa • Feb 03

SDZ: Elevated Expectations Will Confront Ongoing Execution And Manufacturing Setbacks

Analysts have raised their average price target on Sandoz Group by CHF 3 to CHF 60, citing updated assumptions for revenue growth, profit margins and future P/E, in line with recent target increases from several major banks. Analyst Commentary Recent Street research on Sandoz Group has largely focused on recalibrating price targets to reflect updated views on revenue growth, profitability and valuation multiples.
Actualización de narrativa • Jan 20

SDZ: Rising Biosimilar Pipeline Will Face Ongoing Execution And Manufacturing Risks

Narrative Update The updated analyst price target for Sandoz Group reflects a modestly lower fair value estimate alongside slightly higher revenue growth and profit margin assumptions. Recent Street research citing price target moves to CHF 60 and CHF 70 indicates that analysts see room for the shares to better reflect these revised expectations.
Actualización de narrativa • Jan 06

SDZ: Elevated Biosimilar Ambitions Will Face Ongoing Execution And Manufacturing Risks

Analysts have lifted their average price targets on Sandoz Group into a CHF 49 to CHF 70 range, and our updated fair value of CHF 44.42 nudges slightly lower as higher assumed profit margins and revenue growth are offset by a reduced future P/E multiple. Analyst Commentary Recent Street research on Sandoz Group shows a cluster of higher price targets, with targets in the CHF 49 to CHF 70 range.
Actualización de narrativa • Dec 21

SDZ: Elevated Expectations Will Face Execution Risks In Biosimilars Expansion

Sandoz Group's analyst price target has been lifted by roughly CHF 6.50 to around CHF 60, as analysts now factor in stronger revenue growth, modestly higher profit margins, and a richer forward valuation multiple. Analyst Commentary Recent Street research has been broadly constructive on Sandoz Group, with several major firms lifting their price targets into the CHF 49 to CHF 60 range and maintaining positive ratings.
Actualización de narrativa • Dec 07

SDZ: Biosimilar Launch Execution Will Shape Future Multiple And Risk Balance

Sandoz Group’s analyst price target has been nudged higher, with fair value estimates rising by about CHF 1.10 to CHF 52.75 as analysts point to sustained revenue growth expectations and a modestly higher future P E multiple, despite slightly lower margin forecasts. Analyst Commentary Bullish analysts have recently raised their price targets into the CHF 55 to CHF 60 range, signaling growing confidence that Sandoz can sustain above market growth and support a higher valuation multiple.
Actualización de narrativa • Nov 23

SDZ: Sustained Revenue Momentum And Margin Focus Will Shape Fair Value Ahead

The analyst consensus price target for Sandoz Group has increased to CHF 60 from CHF 55. Analysts cite improved margin outlook and sustained revenue growth as key factors supporting the upward revision.
Actualización de narrativa • Nov 09

SDZ: Recent US Launch and European Expansion Will Influence Near-Term Performance

The average analyst price target for Sandoz Group has increased from CHF 50.33 to CHF 52.05, reflecting improved revenue growth forecasts and recent supportive analyst research updates. Analyst Commentary Recent analyst updates reflect a mix of optimism and caution regarding Sandoz Group's valuation, growth prospects, and execution.
Actualización de narrativa • Oct 26

Future Opportunities Will Be Unlocked Through Expanding Pipeline And Global Market Reach

The analyst consensus price target for Sandoz Group rose modestly, increasing from CHF 50.20 to CHF 50.33. Analysts cited stronger revenue growth and improving profit margins in their updated outlooks.
Actualización de narrativa • Oct 12

Biosimilar Pipeline And Global Expansion Will Unlock Future Opportunities

The analyst price target for Sandoz Group has increased by CHF 0.81. This reflects positive sentiment from analysts who cite strong revenue growth and continued profitability improvements as supporting factors.
Nueva narrativa • Aug 17

Biosimilar Pipeline And Global Expansion Will Unlock Future Opportunities

Key Takeaways Accelerated biosimilar launches, improved manufacturing, and strong market share are driving margin expansion and long-term profitability. Strategic focus on international growth and a robust product pipeline positions the company for sustainable earnings momentum.
Artículo de análisis • Jun 25

Sentiment Still Eluding Sandoz Group AG (VTX:SDZ)

You may think that with a price-to-sales (or "P/S") ratio of 2.2x Sandoz Group AG ( VTX:SDZ ) is definitely a stock...

Previsiones de crecimiento de beneficios e ingresos

SWX:SDZ - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
FechaIngresosBeneficiosFlujo de caja libreFlujo de caja operativoNúm. de analistas medio
12/31/202813,3411,9051,6002,17613
12/31/202712,7371,6971,3352,00815
12/31/202612,1651,3747251,49314
12/31/202511,1579148361,594N/A
9/30/202510,8725715481,272N/A
6/30/202510,587227259950N/A
3/31/202510,486114168803N/A
12/31/202410,384N/A76656N/A
9/30/202410,248-4-28581N/A
6/30/202410,111-8-133506N/A
3/31/202410,04535-195434N/A
12/31/20239,97977-258362N/A
9/30/20239,770345136664N/A
6/30/20239,561613530966N/A
3/31/20239,4347316791,095N/A
12/31/20229,3068488281,223N/A
12/31/20219,6789081,0001,354N/A
12/31/20209,6584628131,098N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (17% al año) de SDZ es superior a la tasa de ahorro (0.6%).

Beneficios vs. Mercado: Se prevé que los beneficios (17% al año) de SDZ crezcan más rápidamente que el mercado Swiss (10.9% al año).

Beneficios de alto crecimiento: Se prevé que los beneficios de SDZ crezcan, pero no significativamente.

Ingresos vs. Mercado: Se prevé que los ingresos (5.2% al año) de SDZ crezcan más rápidamente que los del mercado Swiss (4.9% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 5.2% al año) de SDZ crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de SDZ sea baja dentro de 3 años (17.8%).

Descubre empresas en crecimiento

7D

1Y

7D

1Y

7D

1Y

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2026/05/25 05:02
Precio de las acciones al final del día2026/05/22 00:00
Beneficios2025/12/31
Ingresos anuales2025/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Sandoz Group AG está cubierta por 37 analistas. 15 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
Emily FieldBarclays
James GordonBarclays
Sidhartha ModiBarclays